Get Adobe Flash player


Authors: Rozиmenko I.A., Garbuzova V. Yu., Ataman A.V., Obukhova O.A.

Pages: 354-359


Introduction. Transmembrane protein ANKH inorganic pyrophosphate transport regulator (ANKH) is regulates transport of inorganic pyrophosphate (PPi) of the cells into the extracellular environment, thus by playing an important role inhibitor of ectopic calcification of the vascular wall. Protein is contains 7-12 multi-pass transmembrane domains, each of 20 amino acids long. Mutations in this gene have been associated with autosomal dominant craniometaphyseal dysplasia and calcium pyrophosphate dehydrates deposition disease. Persons with recessive mutation of the ANKH gene are suffering from progressive ankylosis with concomitant vascular calcification caused by violation of inorganic pyrophosphate transport. As the calcification of the atherosclerotic plaque is an unto ward prognostic factor of the acute coronary syndrome, the polymorphism of the ANKH gene can be associated with the disease progression.

Purpose. To establish the frequency of allelic variants of the ANKH gene for T134967G polymorphism in patients with acute coronary syndrome (ACS) in persons with normal blood pressure and hypertension.

Materials and Methods. We used venous blood of 118 patients with ACS (22% women and 78% men) aged 40 to 73 years (mean age 55,9±0,89 years) who was hospitalized in the cardiology department of Sumy City Clinical Hospital #1. The control group consisted of 110 patients. Definition of T134967G polymorphism (rs187483) of ANKH gene was performed using PCR with the following restriction fragment length analysis of the allocation of them by electrophoresis in agarose gel. Restriction Hin6I (HinP1I) was used for restriction analysis. Statistical analysis was performed by using the software package SPSS-17. Thus the significance of differences was determined by Pearson’s chi-squered test and Student’s t-test. The value of P < 0,05 was considered as significant.

Results. Genotyping of patients with ACS for T134967G polymorphism of the ANKH gene was allowed setting the frequency with which there are some variants of this gene in patients with normal values of blood pressure (BP) and hypertension. The distribution of allelic variants among patients with ACS with different values of blood pressure was not significantly different (P = 0,949).

In persons who have the T/T genotype in control group and in patients with ACS, the value of BP syst. (P = 0,623), BP diast. (P = 0,065), BP pulse (P = 0,265) and BP mean (P = 0,159) were not significantly different. Values of BP syst. (P = 0,839), BP diast. (P = 0,561), BP pulse (P = 0,407) and BP mean (P = 0,827) in carriers of minor allele (T/G+G/G) were not significantly different between controls and patients with ACS. Patients with ACS – homozygotes for the major allele (T/T) – had significantly higher blood pressure syst. (P <0,0001), BP diast. (P <0,0001), BP pulse (P = 0,0007) and BP mean (P <0,0001) than practically healthy persons.Values of BP syst. (P <0,0001), BP diast. (P = 0,0003), BP pulse (P = 0,0001) and BP mean (P <0,0001) in patients with ACS and genotype T/G+G/G for T134967G polymorphism of the ANKN gene were also significantly higher than in controls.

Conclusion. In patients with ACS, regardless of genotype (T/T or T/G+G/G) values of BP syst., BP diast., BP pulse and BP mean is significantly higher than in the control group.

Key words: ANKH inorganic pyrophosphate transport regulator, acute coronary syndrome, allelic polymorphism.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text


  1. Ho A.M., Johnson M.D., Kingsley D.M. Role of the mouse ank gene in control of tissue calcification and arthritis. Science. 2000; 289:265–270.
  2. Gurley K.A., Reimer R.J., Kingsley D.M. Biochemical and genetic analysis of ANK in arthritis and bone disease. Am J Hum Genet. 2006; 79:1017–1029.
  3. Timms A. E., Zhang Y., Bradbury L., Wordsworth B. P., Brown M. A. Investigation of the Role of ANKH in Ankylosing Spondylitis. Arthritis & rheumatism. 2003; 48(10):2898–2902.
  4. Sweet H.O., Green M.C. Progressive ankylosis, a new skeletal mutation in the mouse. J Hered. 1981; 72(2):87-93.
  5. Nurnberg P., Thiele H., Chandler D., Hohne W. et al. Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia. Nat Genet. 2001; 28:37–41.
  6. Reichenberger E., Tiziani V., Watanabe S., Park L. et al. Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK. Am J Hum Genet. 2001; 68:1321–1326.
  7. Pendleton A., Johnson M.D., Hughes A., Gurley K.A. et al. Mutations in ANKH cause chondrocalcinosis. Am J Hum Genet. 2002; 71:933–940.
  8. Williams C.J., Zhang Y., Timms A., Bonavita G. et al. Autosomal dominant familial calcium pyrophosphate dihydrate deposition disease is caused by mutation in the transmembrane protein ANKH. Am J Hum Genet. 2002; 71:985–991.
  9. Malkin I., Dahmb S., Sukc A., Kobylianskya E., Toliatc M., Ruf N., Livshitsa G., Nqrnberg P. Association of ANKH gene polymorphisms with radiographic hand bone size and geometry in a Chuvasha population. Bone. 2005; 36:365–373.
  10.  Tsui H.W., Inman R.D., Paterson A.D., Reveille J.D., Tsui F.W.L. ANKH variants associated with ankylosing spondylitis: gender differences. Arthritis Research & Therapy. 2005; 7:513-525.
  11. Liu Z., Cui Y., Zhou X., Zhang X., Han J. Association of mineralization-related genes TNAP and ANKH polymorphisms with ankylosing spondylitis in the Chinese Han population. BioScience Trends. 2013; 7(2):89-92.
  12.  Wang J., Wang C., Tsui H.W., Las Heras F., Cheng E.Y. et al. Microcytosis in ank/ank mice and the role of ANKH in promoting erythroid differentiation. Exp Cell Res. 2007; 313:4120–4129.
  13.  Korkmaz C., Sayer J.A. ANKH and Renal Stone Formation in Ankylosing Spondylitis. J Rheumatol. 2012;39:1756.
  14. Abhishek A., Doherty M. Pathophysiology of articular chondrocalcinosis — role of ANKH. Nature Rуvіеws. Rheumatology. 2011; 7:96–104.
  15.  Zhao G., Xu M.J., Zhao M.M., Dai X.Y., Kong W., Gerald M. et al. Activation of nuclear factor-kappa B accelerates vascular calcification by inhibiting progressive ankylosis protein homolog expression. Kidney Int. 2012; 82(1):34–44.
  16.  Braunwald E., Antman E.M., Beasley J.W., Califf R.M., Cheitlin M.D., Hochman J.S. et al.  ACC/AHA guidelinesfor the management of patients with unstable angina and non ST-elevation myocardial infarction: executive summary and recommendations. A report of the american college of cardiology. Circulation. 2000; 102:1193–1209.
  17.  Bertrand M.E., Simoons M.L., Fox K.A., Wallentin L.C., Hamm C.W., McFadden E., et al.   Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. 2002; 23:1809–1840.
  18. Гарбузова В.Ю., Обухова О.А., Атаман Ю.О., Дубовик Є.І. та ін. Частота поліморфізму ApaI гена рецептора вітаміну D у хворих з ішемічним інсультом. Загальна патологія та патологічна фізіологія. 2012; 7(2):142-148.
  19.  Zhang Y., Johnson K., Russell R.G.G., Wordsworth B.P., Carr A.J., Terkeltaub R.A., Brown M.A.. Association of Sporadic Chondrocalcinosis With a -4-Basepair G-to-A Transition in the 5-Untranslated Region of ANKH That Promotes Enhanced Expression of ANKH Protein and Excess Generation of Extracellular Inorganic Pyrophosphate. Arthritis & rheumatism. 2005; 52(4):1110–1117.